Please ensure Javascript is enabled for purposes of website accessibility

Why J&J's Slump Is Sinking the Dow

By Dan Caplinger - Apr 8, 2013 at 11:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors count on defensive stocks, so watch out if they stop working.

Recently, investors have started worrying a lot more that the stock market's rally has come too far too fast. With last week's poor employment report underlining the fact that growth in jobs hasn't kept pace with some other economic indicators, many investors have positioned themselves more defensively in anticipation of a potential downturn in stocks. Moreover, as earnings season begins, companies will reveal what really happened during the first quarter. This morning the stock market reflected that general uncertainty, and by 10:55 a.m. EDT the Dow Jones Industrials (^DJI 0.00%) were down 0.26%, with the broader markets down less sharply.

In their anxiety, investors have gravitated to more defensive stocks in an effort to protect themselves from losses. But this morning, health care stalwart Johnson & Johnson (JNJ -0.89%) is the biggest decliner in the Dow, falling 1.5% as the company got downgraded by an analyst at JPMorgan. The main problem the analyst cited was valuation, as J&J's stock has rocketed higher even as the company faces potential liability linked to recent product recalls. The drop emphasizes how important it is to look at valuation, as even defensive stocks can fall if their prices get too far out of line with their prospects.

UnitedHealth (UNH 1.52%) has also given up ground, down 0.8%. With little news on the company, the move appears just to be a small giveback of some of the massive gains that UnitedHealth and fellow health insurers enjoyed last week when looming Medicare reimbursement rate cuts suddenly turned into modest increases. It increasingly appears that Obamacare may prove more of a positive than a negative for UnitedHealth and its peers, even though the company will have to cover conditions it would previously have excluded.

Finally, Lufkin Industries (NASDAQ: LUFK) soared 38% on news that General Electric (GE 0.72%) will buy the oil field equipment company for $88.50 per share, or $3.1 billion. The move is obviously great news for Lufkin shareholders, but it also shows the extent to which GE is trying to move forward in building up its energy exposure. Given the huge ramp-up in domestic energy-production, GE's bid to become a vital piece of the energy infrastructure and equipment business is clearly a growth opportunity.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
^DJI
$31,490.07 (0.00%) $0.00
General Electric Company Stock Quote
General Electric Company
GE
$75.74 (0.72%) $0.54
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$173.94 (-0.89%) $-1.56
UnitedHealth Group Incorporated Stock Quote
UnitedHealth Group Incorporated
UNH
$478.55 (1.52%) $7.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
327%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.